<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980664</url>
  </required_header>
  <id_info>
    <org_study_id>IN-CN-320-6104</org_study_id>
    <nct_id>NCT04980664</nct_id>
  </id_info>
  <brief_title>Effort to Narrow the Gap Between in Accordance With Guidelines and Consent to Treat CHB Population in East of China</brief_title>
  <acronym>GATE</acronym>
  <official_title>Effort to Narrow the Gap Between in Accordance With Guidelines and Consent to Treat CHB Population in East of China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      China has the world's largest burden of hepatitis B virus (HBV) infection and will be a major&#xD;
      contributor towards the global elimination of hepatitis B disease by 2030. One of the main&#xD;
      issues in the management of patients with chronic HBV infection (CHB) is to maximize the&#xD;
      individuals who need the treatment engaged and retained in care. However, our investigation&#xD;
      revealed that 21.1% patients were treatment eligible but not treated based on Chinese 2019&#xD;
      CHB treatment guidelines, while only 213 (13.9%) patients were indicated-but-not-treated&#xD;
      according to AASLD 2018 Hepatitis B guidance in a real-life cohort study. To maximize the&#xD;
      individuals who need the treatment engaged and retained in care, integrated intervention&#xD;
      strategies to address these treatment barriers are urgently needed. Therefore, we aim to&#xD;
      propose a study to narrow the gap between in accordance with guidelines and consent to treat&#xD;
      CHB population in EAST of China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of indicated-but-not-treated CHB patients.</measure>
    <time_frame>18 months</time_frame>
    <description>The proportion of indicated-but-not-treated CHB patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of lost to follow-up in CHB patients.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of follow-up visit in CHB patients.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Chronic Hepatitis b</condition>
  <arm_group>
    <arm_group_label>Integrated intervention strategies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Integrated intervention strategies</intervention_name>
    <description>Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.</description>
    <arm_group_label>Integrated intervention strategies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Positive HBV surface antigen (HBsAg) for 6 months or more;&#xD;
&#xD;
          2. Elevated ALT levels (&gt;1×ULN) and detectable HBV DNA;&#xD;
&#xD;
          3. Treatment-naïve;&#xD;
&#xD;
          4. Willing to attend this study and able to provide the written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Co-infection with other viral hepatitis and human immunodeficiency virus;&#xD;
&#xD;
          2. Concurrent with other chronic liver diseases, including primary biliary cirrhosis,&#xD;
             autoimmune hepatitis, alcoholic hepatitis, nonalcoholic fatty hepatitis, and&#xD;
             hereditary metabolic liver disease;&#xD;
&#xD;
          3. Patients with liver cirrhosis;&#xD;
&#xD;
          4. Coexistence of hepatocellular carcinoma and other malignant tumor;&#xD;
&#xD;
          5. Underwent liver transplantation before the enrollment;&#xD;
&#xD;
          6. Severe cardiac, renal, respiratory, hematological, or psychiatric illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rui Huang, M.D., Ph.D</last_name>
    <phone>+86-25-83106666</phone>
    <phone_ext>20201</phone_ext>
    <email>doctor_hr@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chao Wu, M.D., Ph.D</last_name>
    <phone>+86-25-83105890</phone>
    <email>dr.wu@nju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Third People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huai'an No.4 People's Hospital</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Infectious Diseases Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Chao Wu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic Hepatitis b</keyword>
  <keyword>Antiviral treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

